Mammoth Biosciences

Mammoth Biosciences

Mammoth Biosciences is an American company based in San Francisco founded on June 1, 2017. Mammoth Biosciences uses CRISPR technology to develop bio-sensing technologies for diagnostics in industries such as healthcare, agriculture, manufacturing, and forensics.

Mammoth Biosciences is an American company based in San Francisco founded on June 1, 2017. Mammoth Biosciences uses CRISPR technology to develop bio-sensing technologies for diagnostics in industries such as healthcare, agriculture, manufacturing, and forensics. Their CRISPR platform utilizes two CRISPR proteins: Cas12 and Cas13. The technology being used by Mammoth Bioscience theoretically allows for the detection of any biomarker and/or disease that contains either RNA and/or DNA.

Products and services
Point of care strip

Mammoth biosciences uses technology licensed from UC Berkley and has created a credit card strip capable of delivering health diagnostics at the point of care in hospital and home settings. Their diagnostic strip works by dropping the desired fluid sample onto the strip and waiting for panels on the strip to change colour indicating the test is complete. The CRISPR technology is embedded within the strip, and if or when the desired reaction takes place a coloured molecule is released called a reporter molecule. Different reporter molecules can be present and eventually build up into colours that can be seen with the naked eye. The user then takes a photo of the strip after the reaction is complete (approximately taking 30 minutes) using a smart phone application developed my Mammoth Biosciences. Users can see the results of their strip test using the app.

Coronavirus diagnostic

Mammoth Biosciences is partnering with UC San Francisco to develop a diagnostic test to identify people infected with coronavirus, SARS-CoV-2 (previously called 2019-nCoV). The new coronavirus strain, identified December 31, 2019 is responsible for an outbreak of disease called COVID-19 that began in Wuhan, China in December, 2019 and was declared a global emergency by the World Health Organization (WHO). For current testing samples are shipped to the Centers for Disease Control and Prevention where the test can take six or more hours to complete. The test being developed by Mammoth Biosciences is expected to take one or two hours and be completed at the doctor’s office. The test would involve a nasal swab being placed in a tube with the CRISPR-Cas system and using a color-changing strip of paper to check for a positive or negative test result. Their test, uses CRISPR-Cas12a-based lateral flow assay and RT-LAMP technology and gives results in less than 40 minutes was validated in patient respiratory swab RNA extracts and results were published in April, 2020.


Mammoth Biosciences has received a disclosed amount of $23min venture capital funding from Mayfield, NFX, 8VC, AME Cloud, Wireframe, Kairos, and Boom Capital.


Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Mammoth Biosciences funding round, August 2018
August 2018
2 Results
Results per page:
Page 1 of 1



Andy Lane

Ashley Tehran

Ashley Tehranchi




James Broughton

Janice Chen

Jennifer Doudna

Lucas Harrington

Pedro Galarza

Trevor Martin

Further reading


After gene-editing, Crispr’s new frontier to detect diseases is closer to becoming a reality

Akshat Rathi

At-home CRISPR kit will diagnose you better than WebMD

Kristin Houser

Jennifer Doudna's latest CRISPR company debuts

Sharon Begley

New startup promises ‘world’s first’ CRISPR-powered disease detection

Dyllan Furness

Xconomy: Home Tests in Mind, Doudna Startup Races Rivals in CRISPR Diagnostics

Alex Lash

Documentaries, videos and podcasts


Mammoth Biosciences launches a CRISPR-powered search engine for disease detection

April 26, 2018

The Mammoth CRISPR Platform

April 26, 2018




January 14, 2021
Mammoth Biosciences, Inc. today announced that it has secured a subcontract with MRIGlobal, the prime contractor with the Defense Advanced Research Projects Agency (DARPA), to develop CRISPR-based diagnostics and biosurveillance technologies for the U.S. Department of Defense (DOD). Mammoth's co-founder and CTO Janice Chen, Ph.D., will lead the team as a Co-Principal Investigator alongside Richard Winegar, Ph.D. and Julie Lucas, Ph.D. from MRIGlobal for the "Detect It with Gene Editin...
August 13, 2020
CB Insights today named Mammoth Biosciences to its second annual Digital Health 150 list, which showcases the 150 most promising private digital health companies in the world. The honor comes on the heels of a landmark year for Mammoth Biosciences, which has seen great success across its CRISPR-enabled platforms for both disease detection and therapeutic applications. The 2020 Digital Health 150 cohort highlights startups that are reimagining the lines of the traditional healthcare...
August 12, 2020
Mammoth Biosciences, Inc., the company behind the world's first CRISPR-based platform for disease detection and the world's smallest known CRISPR Cas nucleases from the Cas14 family, today announced the exclusive licensing of a new CRISPR protein family, Casɸ, from UC Berkeley, for research development and commercialization in all fields. The discovery, which comes from the labs of Mammoth Biosciences' co-founder and CRISPR pioneer Jennifer Doudna at the University of California at...
Darrell Etherington
August 12, 2020
CRISPR pioneer Mammoth Biosciences has secured an exclusive license to a new family of CRISPR proteins, from UC Berkeley, which covers R&D and commercialization across all potential fields. This is a significant addition to Mammoth's intellectual property holdings, since this new family of CRISPR proteins, known as the Casɸ family, is roughly half the size [...]
July 31, 2020
Mammoth Biosciences, Inc. today announced the company has received a contract from the National Institutes of Health (NIH) as part of its $1.5 billion Rapid Acceleration of Diagnostics (RADx) program, making it the first CRISPR based initiative to be funded by the program. The award will help scale Mammoth Biosciences' CRISPR-based DETECTRTM test onto high-throughput automated platforms in commercial labs for COVID-19 diagnostics at an accelerated rate, increasing access to accurate tests...
Darrell Etherington
July 31, 2020
CRISPR tech startup Mammoth Biosciences is among the companies that revealed backing from the National Institutes of Health (NIH) Rapid Accleration of Diagnostics (RADx) program on Friday. Mammoth received a contract to scale up its CRISPR-based SARS-CoV-3 diagnostic test in order to help address the testing shortages across the U.S. Mammoth's CRISPR-based approach could potentially [...]
Gail Dutton
May 22, 2020
The collaboration, announced Wednesday, aims to make disposable, hand-held diagnostics that are as accurate as lab tests and as easy to use as home pregnancy kits.
May 20, 2020
Mammoth Biosciences today announced a collaboration with GSK Consumer Healthcare to develop an accurate, easy-to-use, fully disposable, rapid and handheld test that consumers and healthcare providers in clinics can use to detect active SARS-CoV-2, the novel coronavirus that causes COVID-19. The collaboration will use Mammoth Biosciences' CRISPR-based DETECTRTM platform that can identify and signal the presence of viral RNA strands obtained through a simple
Christine Hall
May 20, 2020
Crunchbase News
Mammoth Biosciences and GSK Consumer Healthcare are using CRISPR-based technology to develop an accurate, rapid and handheld test for COVID-19.
Darrell Etherington
May 20, 2020
California-based Mammoth Biosciences has signed a powerful partner for its development of a CRISPR-based test for COVID-19, which would aim to delivery accurate, fast results using a handheld, disposable testing platform. Mammoth Biosciences will be using its DETECTR platform to develop the test, which recently received validation through a peer-reviewed study published in Nature. Already, [...]
April 19, 2020
Having the option to test for coronavirus contaminations is a basic segment to reviving society -- even a smidgen -- after the underlying flood of COVID-19. So there is a dire requirement for quicker, less expensive tests than the ones accessible at present. One way to deal with the up and coming age of tests is being created by the University of California, San Francisco Medical School and Mammoth Biosciences. In a paper discharged Thursday in the diary Nature Biotechnology, scientists portray a test dependent on another innovation known as CRISPR. CRISPR frameworks have been broadly utilized by scientists to change the hereditary material in living cells. For this situation, a framework known as CRISPR-Cas12 is utilized to perceive hereditary marks of the coronavirus that causes COVID-19 and afterward make slices in it to discharge a fluorescent atom that will show whether the infection is available. Like the test created by the Centers for Disease Control and Prevention, this CRISPR-based test can run various examples without a moment's delay. And keeping in mind that the CDC variant conveys answers in hours, the test from UCSF and Mammoth Biosciences is quicker -- giving outcomes in 30-45 minutes. The test is independent, so it doesn't require complex, costly hardware that is utilized in different tests for the infection.
April 16, 2020
Mammoth Biosciences today announced the publication of a study demonstrating the power of its platform to detect SARS-CoV-2 from respiratory swab RNA extracts in under 45 minutes. The study, published in Nature Biotechnology , contains the first peer-reviewed data using CRISPR diagnostics for COVID-19, with the largest set of patient samples to-date. There is an urgent need for rapid and accessible testing of the novel coronavirus for an effective public health response. The curre...
Darrell Etherington
April 16, 2020
SF-based CRISPR diagnostics startup Mammoth Biosciences has published the first peer-reviewed study that shows validation of using its testing method to detect the presence of COVID-19 in patients. The study, published in Nature, shows performance on par with existing PCR-based molecular tests, the one ones currently authorized for use by the FDA to test for [...]
Amos Zeeberg
April 14, 2020
The FDA still hasn't approved at-home tests. But faster, more distributed tech is on the way to clinics and ERs--and is just what the doctor ordered.
Cormac Sheridan
March 23, 2020
Scientific American
Scientific American is the essential guide to the most awe-inspiring advances in science and technology, explaining how they change our understanding of the world and shape our lives.
Megan Molteni
February 5, 2020
The FDA has given emergency authorization to a new test that promises to help public health labs meet a potential surge in cases.
January 30, 2020
Mammoth Biosciences, the company behind the world's first CRISPR-based disease detection platform, today announced an oversubscribed round of $45 million in its Series B. The raise is led by Decheng Capital and has participation from Mayfield, NFX, Verily, Brook Byers, Plum Alley, Pacific 8, aMoon, and others. The capital will fuel the company's further development of CRISPR diagnostics and next-generation CRISPR products as it extends its platform to include gene-editing and therapeutics...
December 16, 2019
Mammoth Biosciences, the company developing the next generation of CRISPR products, today announced the addition of two key members to its executive team. The expansion of the team supports Mammoth's growth in the life sciences market as the company continues to discover and democratize access to CRISPR systems. Peter Nell, Ph.D. joins Mammoth Biosciences as Chief Business Officer and Head of Therapeutics. In this role, he'll leverage his vast business development and corporate strate...


Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.